Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has provided an update.
Cizzle Biotechnology has arranged a new unsecured funding facility of up to £250,000 in convertible loan notes with existing investor Frazer Lang, extending previously agreed note programmes that now total £400,000 already drawn. The new facility can be tapped in three tranches between May and July 2026, carries no interest or fees, is convertible at 1.4p per share until 30 October 2026, and is structured so Lang will seek only equity redemption rather than cash.
The company plans to use the facility, if needed, to support the commercial launch of its CIZ1B blood test for early lung cancer detection in North America, alongside rollout efforts in the UK and Europe and ongoing work with the Moffitt Cancer Center. In connection with the deal, Cizzle has granted Lang warrants over 10 million additional shares at 2.5p, lifting his warrant holding to 22.5 million and potentially increasing his ownership to about 21%, underscoring strong insider backing as the company positions for growth in 2026.
The most recent analyst rating on (GB:CIZ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Cizzle Biotechnology Holdings PLC stock, see the GB:CIZ Stock Forecast page.
Spark’s Take on CIZ Stock
According to Spark, TipRanks’ AI Analyst, CIZ is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.
To see Spark’s full report on CIZ stock, click here.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings is a UK-based diagnostics developer focused on non-invasive, cost-effective blood tests for early cancer detection, particularly lung cancer. Its core product is the CIZ1B biomarker test, which targets early-stage lung cancer and is being commercialised through licensing deals and collaborations with leading cancer centres in North America, the UK and Europe.
Average Trading Volume: 993,418
Technical Sentiment Signal: Buy
Current Market Cap: £8.52M
For a thorough assessment of CIZ stock, go to TipRanks’ Stock Analysis page.